Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F182112 in Systemic Lupus Erythematosus
NCT07829614Phase 1Recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, single-arm trial of F182112 in systemic lupus erythematosus (SLE), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Incidence of Adverse Events (AE) and Serious Adverse Events (SAE) at 28 days. Started Oct 2025; status: recruiting.
02
Drugs
F182112
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07829614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829614.